Samsung Bioepis sues Fresenius Kabi over patent for generic Humira

Intellectual Property 2022-08-04 11:12 pm By Sam Matthews | Melbourne

Please login to bookmark

Samsung Bioepis Australia has sued fellow biotechnology company Fresenius Kabi over a biosimilar of top selling immunosuppressant drug Humira, saying the invention ‘does not achieve the promise’ of a better formulation using fewer ingredients.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au